db/db mice with PAX6 replenishment displayed a long‐term improvement in hyperglycemia and elevated serum insulin level with an overall trend up to 5 months compared to db/db mice receiving AAV‐Ctrl (Fig 4A and B). This evidence concerns the gene PAX6 and Hyperglycemia.